


**Claims:**

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



5


wherein

R¹ and R² independently represent hydrogen or C<sub>1-6</sub> alkyl or R¹ is linked to R² to form a group (CH<sub>2</sub>)<sub>2</sub>, (CH<sub>2</sub>)<sub>3</sub> or (CH<sub>2</sub>)<sub>4</sub>;


10 p represents 1 or 2;

m represents an integer from 1 to 4, when m is an integer greater than 1, two R² groups may instead be linked to form a group CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub>;


Q represents a group of formula (i), (ii), (iii) or (iv):




15




20





wherein [N] and [S] represent the attachment points for the groups



- 5 one of X and Y represents  $-N=$  and the other represents  $-N(R^5)-$ ;
- R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen, halogen, cyano,  $-CF_3$ ,  $-OCF_3$ , C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl or a group  $-CONR^6R^7$ ;
- 10 R<sup>3a</sup> and R<sup>5</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl;
- R<sup>6</sup> and R<sup>7</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;
- n and q independently represent 1 or 2;
- r and s independently represent an integer from 1 to 3;
- 15 A represents a group  $-Ar^1$  or  $-Ar^2Ar^3$ ;
- Ar<sup>1</sup>, Ar<sup>2</sup> and Ar<sup>3</sup> independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub> alkyl,
- 20 trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub> alkoxy, arylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxy carbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamido, C<sub>1-6</sub> alkylamido, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido,
- 25 arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group CONR<sup>8</sup>R<sup>9</sup> or SO<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;
- 30 or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E16 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

5

4. A compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders.

5. A pharmaceutical composition which comprises a compound according to claim 1

10 or claim 2 and a pharmaceutically acceptable carrier or excipient.